USPTO serial 79209271
MAST
Reviewed by CopyMark Law Group
Reg. 6082227Status 706Renewal
- Filing date
- Status date
- Registration date
- Jun 23, 2020
- Examiner
- SHANOSKI, JOANNA MARIE
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with MAST?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $1,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey A. Smith
Jeffrey A. Smith Millen White Zelano and Branigan PC2200 Clarendon BoulevardSuite 1400Arlington, VA 22201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science; reagents for scientific and research use and clinical and medical laboratory use; chemical reagents for scientific and research use and clinical and medical laboratory use; molecular reagents for scientific and research use and clinical and medical laboratory use; biological reagents for scientific and research use and clinical and medical laboratory use; microbiological reagents for scientific and research use and clinical and medical laboratory use; antibiotic susceptibility reagents for scientific and research use and clinical and medical laboratory use; cell growth media for the cultivation and growth of bacteria, fungi and yeast cells from clinical specimens or reference strains for use in laboratories, near patient testing laboratory facilities, and for diagnostic research purposes; Kits comprising chemical, molecular, biological and microbiological reagents for scientific, research, and clinical and medical laboratory use; Kits comprising chemical reagents for conducting enzyme-linked immunosorbent assays (ELISA) for scientific and research use and clinical and medical laboratory use; Kits comprising chemical reagents for conducting thermal amplification assays for scientific and research use, and clinical and medical laboratory use; Kits comprising chemical reagents for thermal amplification or detection of nucleic targets for scientific and research use, and clinical and medical laboratory use; assay preparations for scientific and research use and clinical laboratory use; Test kits for detecting antibodies, other than for medical or veterinary use, comprising immunofluorescence dyes, enzyme immunoassay reagents, and Western blot electrophoreses and protein gel reagents, all for use for scientific and research use, and clinical or medical laboratory use; Chemical cell culture media supplements and test kits comprised of chemical cell culture media supplements for use in laboratories, near patient testing facilities for research purposes related to identification and susceptibility testing for scientific and research use, and clinical or medical laboratory use; chemicals for use in the cryopreservation of organisms for scientific use, research use and clinical or medical laboratory use; chemical reagents for molecular biology scientific research and for use in clinical and medical laboratories; cell culture media for use in laboratories, near patient testing facilities for diagnostic research purposes, and clinical or medical laboratory use; reagents for use in scientific apparatus for antibiotic susceptibility analysis; nutrients for use in scientific apparatus for microbiological analysis; Biochemical reagents for the identification and detection of bacteria for non-medical purposes; biochemical reagents for clinical or medical laboratory use; bacterial agglutinating antisera for clinical or medical laboratory use; Laboratory chemicals, namely, stained febrile antigens; Laboratory chemicals, namely, latex for agglutination tests | ACTIVE | — |
| 005 | Pharmaceutical preparations, namely, preparations for use in antibiotic susceptibility tests for the detection and identification of infectious pathogens present in clinical and reference specimens and for use in antibiotic susceptibility tests for the detection and identification of infectious pathogens present in clinical and reference specimens; veterinary diagnostic preparations; sanitary preparations for medical use and disinfectants; nutrient media for bacteriological cultures for use in medical laboratories and near patient testing facilities for diagnostic purposes in human medicine; Nutrient media for use in medical diagnostic testing laboratories and near patient medical diagnostic testing facilities; antibiotic susceptibility tests for microbiological and infectious disease detection for medical purposes; Diagnostic reagents for medical or veterinary purposes; Kits comprising chemical, molecular, biological and microbiological reagents for medical or medical veterinary purposes; biological or chemical reagents for use in molecular biology for medical or veterinary purposes; Kits consisting of reagents for conducting enzyme-linked immune-absorbent assays (ELISA) for medical or veterinary purposes; chemical, biological, molecular and microbiological reagents for medical or veterinary purposes; Kits consisting of chemical reagents for medical use for conducting thermal amplification assays; Kits consisting of chemical reagents for medical use for thermal amplification or detection of nucleic targets; Medicated serums containing antigens for the treatment of allergies; Diagnostic antibodies for use in disease testing; antibodies for immunodiagnostic purposes; Intercalcating agents, namely, secondary antibody, conjugate, DNA-DNA, protein-protein and DNA-protein linking agents for medical or veterinary use; Medical diagnostic tests comprised of reagents and assays for detecting antibodies; proteins for medical use in binding antibodies; Medical testing kits comprising reagents for infectious disease diagnosis; Antimicrobial preparations for use in the cryopreservation of organisms; Medical diagnostic molecular reagents for use in the identification and detection of bacteria, veterinary pathogens and other infectious organisms and the diagnosis of urine infections and autoimmune diseases and none of the above being for allergy tests; Medical diagnostic reagents for urine examination reagents for the detection of occult blood in feces; reagents for immunodiagnostic tests, namely, the diagnosis of autoimmune disease; Diagnostic molecular biology kits composed primarily of reagents and assays for pathogenic detection and identification | ACTIVE | — |
| 009 | Apparatus for recording, transmission or reproduction of sound or images; data processing equipment and computers; apparatus for measuring inoculated bacterial cultures; laboratory image analysing apparatus and instruments for detection, diagnosis and identification of treatment options of the causative agents of diseases and the capture of fluorescent, luminescent chromatic or electrical signal output upon excitation at a given wavelength from a nucleic acid amplification test which has intercalating dyes, flurophores or other tagging mechanisms; analytical apparatus for microorganism identification and the reading of antibiotic susceptibility tests, namely, recorded computer software and computer hardware used in image analysis; Recorded computer programs and software for use in molecular biology for the reading, analysis and correlation of data and reporting of microorganism identification from samples; Measuring apparatus for use in quantifying of biological materials in assay testing; laboratory research bacterial storage and cultivation apparatus; storage retrieval systems for the preservation of organisms consisting of recorded computer software for controlling insertion, removal, and storage temperature of tissue samples, lockable petri dishes, and laboratory robotic arms; Parts specially adapted for laboratory research testing equipment, namely, antibiotic and antifungal susceptibility discs, rings and tablets, paper antibiotic and antifungal susceptibility discs, rings, tablets and strips, antibiotic resistance detection discs, rings, and tablets, and paper antibiotic resistance detection discs, rings, tablets and strips; Recorded software for urine testing, antibiotic susceptibility testing, identification and detection of bacteria, veterinary pathogens and other infectious organisms and the diagnosis of urine infections and autoimmune diseases; laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids, and parts therefor sold together as a unit, namely, analysers, dispensers, inoculators, interface modules and marker pins, and analysers, dispensers, inoculators, interface modules and marker pins for urine testing; Laboratory instruments for use in the preparation of samples, namely, instruments for the allocation of clinical specimen onto microtiter plates and instruments for dispensing of clinical specimens and antibiotic susceptibility discs onto microbiological culture plates; laboratory pre-poured media 96-Well plates for bacterial antibiotic susceptibility testing (AST) or identification (ID) and 90-100mm or 150mm microbiological culture plates containing Mueller Hinton agar for urine screening; laboratory glassware, namely, vials and wells for storage and preservation of bacteria; Chemical analyzers for reading laboratory sample cards for occult blood tests; Chemical analyzers for reading laboratory reaction cards including latex agglutination reaction cards; laboratory instruments, namely, chemical analyzers for reading discs, strips and circles for identification and detection of bacteria; Laboratory reaction tubes; turbidimeters; laboratory instruments, namely, amplification units for molecular biology tests for the detection of target DNA by measuring the increase in the signal output from the diagnostic assay; data processors for processing patient specimen data in medical diagnostics, reading and analysis of diagnostic test result data, and validation of analyser derived test results; recorded software operating programs for use with medical diagnostic testing and analysis equipment; apparatus for microbiological laboratory testing, namely, microscopes and microbiological safety cabinets; parts and fittings for the aforementioned goods, namely, inoculating pins, inoculating pin holders, inoculum pots, bar code readers, all-in-one PCs in drive and tablet computer formats, electronic cables, power adapters, marker assemblies, magnifiers, printers, racks for holding microtiter plates, molecular platform amplification units comprising drive modules, power modules and HMI modules and power cables, LEDs, circuit boards, bar code readers and HMIs in tablet computer form, antibiotic susceptibility testing disc dispensers, desiccant packs specially adapted for laboratory equipment, disc dispenser canisters, disc dispenser spares for repair | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mast Group Limited
- Other trademarks owned by Mast Group Limited
- Other trademarks owned by Mast Group Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Similar marks named MAST
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 17, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Sep 17, 2026 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Sep 7, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 23, 2026 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jun 23, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 1, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 9, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 8, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 23, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 14, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 23, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 18, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 18, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 3, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 2, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 2, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 27, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 6, 2019 | IRRH | IRREGULARITY FROM IB EXAMINED BY MPU | — |
| Oct 23, 2019 | IRRF | IRREGULARITY ON REFUSAL FROM IB | — |
| Aug 30, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2019 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Feb 12, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 30, 2018 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 14, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 14, 2018 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 12, 2018 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 12, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 12, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 12, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 24, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 24, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 23, 2018 | ALIE | ASSIGNED TO LIE | — |
| Jan 8, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 4, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 4, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 28, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 8, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 8, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 28, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 27, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 9, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 9, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 8, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |